NPM1 and intrahepatic cholangiocarcinoma: Regardless of these differences in the WHO classification and the ICC, CMML NPM1 mutated appears to herald a particularly aggressive clinical course with a median overall survival of 12.5 months compared to 20.5 months for NPM1 wild-type patients [15].